[Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease]. / Klinicheskie i farmakologicheskie aspekty antisekretornoi terapii gastroézofageal'noi refliuksnoi bolezni.

The article discloses the results of an open prospective randomized study of the antisecretory therapy efficiency conducted among 20 patients with gastroesophageal refluxed disease (erosive form, non-complicated course). The selection of the optimal antisecretory drug was substantiated from the point of view of the clinic-diagnostic and pharmacoeconomic assessment of the results of the above-mentioned therapy conducted with the application of rabeprosole (pariet) and its generic omeprosole (omez).